Respiratory syncytial virus (RSV) infection is an important cause of respiratory mortality in immunosuppressed patients, including bone marrow transplant (BMT) recipients. The presence of lower respiratory tract infection and infection in the pre-engraftment phase of BMT is believed to confer a poor prognosis. Three patients who underwent allogeneic BMT at our institution developed RSV pneumonia over 1 year post BMT, with the underlying disease in remission. All three were hypoxic with extensive pulmonary disease at presentation. Treatment consisted of aerosolized ribavirin and intravenous immune globulin with successful clearing of viral shedding and excellent clinical outcomes. RSV infection is probably less severe in the late post-BMT period, but needs to be considered early in the differential diagnosis of pulmonary infiltrates in this patient population. Bone Marrow Transplantation (2001) 27, 1071-1073. Keywords: RSV infection; late; BMT; ribavirin Respiratory syncytial virus (RSV) is a common pediatric pathogen with a predilection for winter outbreaks. In the adult population, RSV infections are increasingly recognized as important causes of respiratory mortality, primarily in immunosuppressed patients, including allogeneic bone marrow transplant (BMT) recipients. The clinical presentation in these sub-groups is frequently as an upper respiratory tract infection (URTI) that can rapidly progress to viral pneumonia if untreated. This progression from URTI to pneumonia is much higher in the immediate posttransplant period.
Respiratory syncytial virus (RSV) is a common pediatric pathogen with a predilection for winter outbreaks. In the adult population, RSV infections are increasingly recognized as important causes of respiratory mortality, primarily in immunosuppressed patients, including allogeneic bone marrow transplant (BMT) recipients. The clinical presentation in these sub-groups is frequently as an upper respiratory tract infection (URTI) that can rapidly progress to viral pneumonia if untreated. This progression from URTI to pneumonia is much higher in the immediate posttransplant period.
1,2 RSV pneumonia in allogeneic BMT patients has been associated with mortality rates between 60% and 80%, despite aggressive treatment. Negative predictors of outcome following RSV infection in BMT recipients remain ill-defined, but include infection in the pre- engraftment period, lower respiratory tract infection, delay in initiation of ribavirin therapy, and possibly unrelated donor transplants and acute myeloid leukemia (AML) as the underlying disease. [1] [2] [3] [4] [5] There are few data regarding RSV infections in adult BMT recipients 1 year or more after transplant. We report three such cases of RSV infection at the Roswell Park Cancer Institute (Buffalo, NY) treated successfully with aerosolized ribavirin and intravenous immune globulin (IVIG) during the winter of 1999-2000. The absolute neutrophil count was normal and the underlying disease was in complete remission in all three patients.
Case reports
Patient 1 is a 24-year-old female, who was 384 days following an allogeneic BMT for chronic myelogenous leukemia from an HLA-matched sibling donor. The conditioning regimen used for BMT was busulfan and cyclophosphamide. The post-BMT course was complicated by acute and chronic graft-versus-host disease (GVHD) requiring methyprednisolone, cyclosporine and tacrolimus therapy. She had completed a course of immunosuppressive therapy 2 weeks prior to detection of RSV infection. The patient was receiving trimethoprim/sulfamethoxazole, penicillin and acyclovir prophylaxis. Presenting symptoms included sinus congestion, cough with mucopurulent expectoration and dyspnea on exertion. Her 15-month-old infant had had symptoms of URTI within the preceding weeks. She was afebrile and hemodynamically stable. Pulmonary examination revealed clear lung fields. Pulse oximetry upon ambulation dropped to 80% on room air and she was admitted to hospital. Chest radiograph was normal. Computerized tomogram (CT) of the sinuses revealed pan-sinusitis. Chest CT scan showed bilateral interstitial infiltrates predominantly reticular with a nodular component. Ampicillin/ sulbactam and levofloxacin (to cover atypical bacteria) were begun. A bronchoscopic alveolar lavage (BAL) done the next day revealed mild neutrophilic pleocytosis. Bacterial culture grew viridans streptococci, felt to be an oral contaminant. Fungal and mycobacterial cultures were negative. RSV was detected by immunofluorescence assay (IFA) in the bronchial washings, while other viral studies were negative. Aerosolized ribavirin therapy (6 g over 18 h each day at 20 mg/ml, for 7 days via a respiratory small particle aerosol generator 'SPAG unit') and concurrent IVIG (500 mg/kg/dose every other day for four doses) were begun. Antibiotics were continued for 10 days. She had complete resolution of symptoms and reversal of hypoxia. A follow-up nasopharyngeal (NP) swab was negative for RSV. Complete radiographic resolution of pulmonary findings was documented on a CT scan 1 month after completion of treatment.
Patient 2 is a 32-year-old male who had undergone an HLA-matched sibling allogeneic BMT for refractory small lymphocytic lymphoma approximately 883 days prior to developing RSV infection. The malignancy was in complete remission. The conditioning regimen used for his BMT was high-dose etoposide and cyclophosphamide with total body radiation. GVHD prophylaxis and treatment included methylprednisolone, cyclosporine and tacrolimus. The post-transplant course was complicated by cytomegalovirus pneumonitis requiring ganciclovir therapy. In addition, he developed bronchiolitis obliterans organizing pneumonia (BOOP) and he required chronic low-dose corticosteroid (methylprednisolone 6 mg/day) therapy with intermittent pulse corticosteroid treatment for exacerbation of BOOP. Serial chest radiographs at diagnosis of BOOP showed a bilateral interstitial pulmonary process, and lung function tests revealed restrictive lung disease. This patient was admitted to the hospital for worsening pulmonary symptoms and cough, expectoration and dyspnea. Concomitant fever of 38.8°C, myalgia, nausea, headache and dizziness were present. On examination, he appeared ill with tachycardia and orthostatic hypotension, initially requiring intravenous fluid hydration. Pulse oximetry was 91% to 94% at rest on room air. Bilateral rales were present on pulmonary examination. Chest radiograph revealed chronic interstitial changes (unchanged from earlier radiographs) without any infiltrate. Ceftriaxone and erythromycin were begun, and pulse corticosteroids were initiated for possible exacerbation of BOOP. An NP swab done the next day was positive for RSV (by IFA) and influenza A. An expectorated sputum culture showed normal respiratory tract flora. The steroid dose was rapidly tapered to that pre-admission and antibiotics were discontinued after 3 days of therapy. The patient was treated with an aerosolized ribavirin regimen similar to that of patient 1, and with three doses of IVIG, with a successful return to his baseline pulmonary status.
Patient 3 is a 36-year-old male with follicular smallcleaved cell non-Hodgkin's lymphoma who underwent an HLA-matched sibling allogeneic BMT in June 1997, following a conditioning regimen of high-dose etoposide and cyclophosphamide with total body irradiation. His disease was in complete remission at the time of RSV infection. Cyclosporine and Orthoclone OKT3 (Muromonab-CD3) were used as part of a clinical trial for GVHD prophylaxis, and he was treated with methylprednisolone, cyclosporine and tacrolimus for acute and chronic GVHD. All immunosuppression had been discontinued briefly before reinitiation of methylprednisolone for chronic GVHD. At approximately 810 days after BMT, the patient developed BOOP, diagnosed by an open lung biopsy, requiring continuation of corticosteroid therapy. Five months later (approximately 975 days following BMT), he developed flu-like symptoms, cough with mucopurulent expectoration, and fever of 39.2°C. Physical examination revealed bilateral rales, with decreased breath sounds at the left lung base. Pulse-oximetry was 82% on room air. The dose of methylprednisolone was 16 mg/day at the time, and prophylaxis with penicillin, acyclovir, itraconazole and dapsone was ongoing. A CT scan of the chest showed diffuse airspace disease, with small pericardial and left pleural effusions. He was initially treated with ceftazidime, clarithromycin and higher doses of methylprednisolone. Initial sputum culture showed normal respiratory flora and an NP swab was negative for RSV by the rapid IFA method. BAL showed neutrophilic pleocytosis. Bacterial and fungal cultures were negative. RSV infection was detected by IFA in the BAL specimen. The patient was treated with aerosolized ribavirin and IVIG in a similar manner to patients 1 and 2. The corticosteroid dose was rapidly tapered to preadmission level and only clarithromycin was continued. His respiratory symptoms and fever resolved and he was discharged on hospital day 7 after completion of ribavirin and IVIG therapy. A follow-up NP swab on day 13 post treatment was positive for RSV by IFA. Although the patient remained asymptomatic, his ambulatory pulse oximetry was 89%. CT scan of the chest showed an overall significant improvement. The patient's level of hypoxia prompted us to reinitiate ribavirin and IVIG therapy while awaiting RSV culture results. An NP swab after the second course was negative for RSV by IFA and culture. Pulse oximetry at completion of all therapy ranged from 94% to 97% on room air and an additional CT scan of the chest showed further partial clearing of the interstitial opacities.
Discussion
Traditionally, the etiology of community-acquired pneumonia in adult BMT patients includes bacteria, fungi and herpesviruses. 6 Community-acquired respiratory viral infections occur in 15-30% of BMT patients each year. As is increasingly being recognized, one-third to one-half of these are due to RSV. 7, 8 Given its propensity to cause lifethreatening infection in this cohort of patients, RSV disease must be considered in the differential diagnosis of fever and pulmonary infiltrates and/or abnormal sinus radiographs in immunocompromised adults.
All three cases described occurred within 4 weeks of one another in the winter of 1999-2000 in Buffalo, NY. Two patients were receiving low doses of corticosteroids for BOOP, but no additional immunosuppression. RSV infection in these patients was probably community-acquired and began as an URTI progressing rapidly to involve the lower respiratory tract with resultant symptomatology and hypoxia. One patient did have exposure to an infant with upper respiratory tract symptoms and all three were seen in the outpatient clinic within the preceding month. No case of RSV infection in our series resulted in respiratory failure. The successful outcome in our patients was probably related to early diagnosis, prompt treatment and possibly to a more intact immune system given their engraftment status and late time from BMT.
We reviewed the literature concerning RSV infection in adult allogeneic BMT patients, specifically attempting to identify those reports of infection occurring late in the postengraftment period. In an early report, Englund et al 9 documented RSV disease in six adult BMT patients. Of these six, three who survived had RSV infection documented at a median of 82 days post allogeneic BMT (range 7-157 days). Sinusitis was a presenting feature in two of them. In another series of RSV-induced acute lung injury, Hertz et al 5 reported two cases of RSV infection occurring 150 and 400 days post allogeneic BMT with six others contracting the infection pre-engraftment. Both post-engraftment cases were treated with immunosuppressive therapy for chronic GVHD, had clinical but not radiographic evidence of lower respiratory tract infection, and survived with ribavirin aerosol therapy. In the pre-engrafted group, four out of six patients died. Sinus radiograph abnormalities were present in seven of the eight patients.
In two large BMT centers, 2,7 BMT recipients tended to develop RSV pneumonia more frequently whilst neutropenic than following myeloid engraftment. Early initiation of therapy was associated with a favorable outcome. In the MD Anderson series, 7 only two of nine patients with RSV infection occurring more than 6 months after BMT developed pneumonia and both had profound chemotherapy-induced myelosuppression following treatment for recurrent disease. In a retrospective analysis spanning a 5-year period, McCarthy and colleagues 4 examined the incidence and outcome of RSV infection in BMT recipients. Approximately 6% (26/336) of allogeneic stem cell transplant recipients were diagnosed with RSV infection. Five patients (19.2%) died as a direct result of RSV. The only two patients infected with RSV at more than 18 months post BMT were still profoundly immunosuppressed at the time, receiving treatment for resistant malignancy. The presence of LRTI was associated with increased mortality. Engraftment status and treatment for RSV did not correlate with outcome.
In a recent prospective open-label pilot trial, 10 prompt treatment of RSV URTI in BMT recipients with aerosolized ribavirin and IVIG was safe and was associated with less progression to pneumonia and mortality than in historical controls. RSV infection was complicated by pneumonia in four of nine patients at 30 days or less after BMT, and two of these patients died. In contrast, none of five patients with RSV infection occurring 30 days after transplant developed pneumonia or died.
In our series, all three allogeneic BMT recipients were more than 1 year post BMT and in complete disease remission. Although hypoxic at presentation with clinical and/or radiographic evidence of LRTI, none required assisted ventilation, and all improved rapidly following therapy with aerosolized ribavirin and IVIG resulting in successful clearing of viral shedding. The immunosuppression associated with corticosteroid use for chronic GVHD control cannot be discounted as a factor predisposing to the development of LRTI in two of these patients. Our practice is to culture naso-pharyngeal washings after completion of therapy to document resolution of infection. If the RSV culture is positive we recommend re-treatment with ribavirin and immunoglobulin. Since RSV antigen may persist Bone Marrow Transplantation for several days after clearance of infection, the decision to re-treat should be based on RSV culture data. In patient 3, re-treatment with ribavirin and IVIG was undertaken on the clinical premise of incompletely cleared infection in view of persistent hypoxia after one course of therapy.
RSV-specific immune globulin and the monoclonal antibody Palivizumab have been used as therapy and as prophylaxis against RSV in high-risk infants. It is unclear whether such preparations have additional value compared with IVIG in hematologic transplant recipients.
In conclusion, RSV infection should be considered in the differential diagnosis of fever and respiratory symptoms in BMT patients, even in the late BMT period and especially in association with abnormal chest and sinus radiographs. The disease appears to have a less aggressive course in the late compared with the early post-BMT period. It is important to identify RSV infection while limited to the upper respiratory tract in view of distinct adversity in the face of lower respiratory tract disease. RSV pneumonia can be safely and successfully treated in the late post-allogeneic BMT period and, although no randomized studies exist, early administration of aerosolized ribavirin and IVIG therapy should be strongly considered for RSV infection in this patient population.
